StockIQ.techBiogen Inc. (BIIB) Stock Analysis
Free AI-powered analysis and research for Biogen Inc. stock
Sector: Healthcare
BIIB snapshot
Data as of 3 Nov 2026 close. Updated daily.
Biogen Inc. scores 61/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 92% of its 52-week range, up 65.2% over the past year. Latest reported figures show a profit margin of 3.4%, return on equity of 1.9% and revenue growth of +10.6%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (108.4): -10
- Weak Profit Margin (3.4%): -8
- Weak ROE (1.9%): -6
- Strong Long-term Uptrend: +8
- Strong Rise (+65.2% over 1 year): +10
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full BIIB report
Biogen Inc. (BIIB) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze BIIB Now →📰 Latest Update
Biogen Q3 Earnings Call Highlights
Wed, October 28, 2026 at 10:04 PM UTC 2 min read
Biogen reported its Q3 earnings, showcasing a stronger-than-expected performance driven by increased sales of its Alzheimer's drug, Aduhelm, and cost-cutting measures. The company's focus on innovation and pipeline development is crucial for sustaining growth amid competitive pressures in the biotech sector. Investors should note the positive outlook, as it indicates potential for future revenue stability and growth, reinforcing confidence in Biogen's strategic direction.